Last updated: Jun 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06997497 | 3 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | KRAS G12C -- covalent inhibitor |
| NCT07235293 | 2 | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | CD47 + PD-L1 -- bispecific antibody (DSP107) combined with PD-L1 inhibitor (Atezolizumab) |
| NCT06882915 | 1 | Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study | Thymidine phosphorylase + VEGF + PD-1 -- nucleoside analog + anti-angiogenic + immune checkpoint blockade combination |
| NCT06783491 | 3 | Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer | DNA crosslinking -- mitomycin + DNA synthesis inhibition -- FOLFOX chemotherapy |
| NCT07446322 | 2 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | VEGF -- monoclonal antibody (bevacizumab); DNA synthesis + topoisomerase I -- chemotherapy (FOLFIRI); Oncolytic virus (pelareorep) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 71 |
| Sun Yat-sen University | 52 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 26 |
| M.D. Anderson Cancer Center | 17 |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | 15 |
Countries/regions with the most active trial sites for colorectal cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 21, 2026 | NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | RNA polymerase I transcription + PD-1 -- small molecule inhibitor + immune checkpoint inhibitor |
| Nov 1, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody) |
| Sep 2026 | NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers | Nectin-4 -- bispecific antibody (CT-202) |
| Aug 2026 | NCT07487168 | Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors | DNA crosslinking -- mitomycin C (alkylating agent) |
| Jul 30, 2026 | NCT07610707 | YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases | CTLA-4 -- mRNA-encoded antibody (biological) |
| Jul 21, 2026 | NCT07363408 | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer | PD-1 + unknown target (ADG126) -- immune checkpoint blockade + unknown mechanism |
| Jul 15, 2026 | NCT07621159 | A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer | MDM2 -- small molecule inhibitor (HDM2017); VEGFR -- tyrosine kinase inhibitor (Fruquintinib) |
| Jul 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
You've seen the colorectal cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.